Financial news
Written by: Jingjing He
2020-02-21 10:15
Last updated: 2020-02-21 10:15Tailing Pharmaceutical (1011) announced that the company's subsidiary Suzhou First Pharmaceutical Co., Ltd., a compound drug for the treatment of bipolar disorder "Shusi" (general name: quetiapine fumarate tablet) recently Nikkei China State Food and Drug Administration approved the consistency evaluation. The company stated that after the "Shu Si" passed the consistency evaluation, it will further consolidate the Group's market position as a domestic psychiatric treatment.
Stimulated by the news, Tailing Pharmaceutical's stock price soared to 0.27 yuan, up to 0.237 yuan, up 19%, and temporarily recorded 11.22 million yuan in transactions.
Transaction stock